person · Reporting owner

Kiener Peter A

Disclosed activity across 4 companies

Tapewire entity: 69958
SEC CIK: 0001328146

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Cue Biopharma, Inc.CUE · Entity 6301	Director	January 02, 2026	January 06, 2026
PALVELLA THERAPEUTICS, INC.PIRS · Entity 4452	Director	June 21, 2023	June 23, 2023

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Cue Biopharma, Inc.

Report date January 02, 2026 · Filed January 06, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.34 · Expires 2036-01-01	Direct	24,400	Reported balance After 2026-01-02 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-01-02 · Grant · Acquired 24,400 · Balance 24,400 F1: Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy. F2: This stock option becomes fully exercisable on the first anniversary of the grant date.

Filing footnotes · ownership attribution and instrument terms

F1: Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy.

F2: This stock option becomes fully exercisable on the first anniversary of the grant date.

PALVELLA THERAPEUTICS, INC.

Report date June 21, 2023 · Filed June 23, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.26 · Expires 2033-06-21	Direct	40,000	Reported balance After 2023-06-21 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2023-06-21 · Grant · Acquired 40,000 · Balance 40,000 F1: The stock option will vest as to 100% of the underlying shares on the date of the Company's 2024 annual stockholders meeting, subject to the Reporting Person's continued service as a director through the vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The stock option will vest as to 100% of the underlying shares on the date of the Company's 2024 annual stockholders meeting, subject to the Reporting Person's continued service as a director through the vesting date.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

LAVA Therapeutics NV

Report date November 13, 2025 · Filed November 17, 2025

Section 16 reporting ended · disclosed 2025-11-17. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Share Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.93 · Expires 2035-02-12	Direct	0	Reported balance After 2025-11-13 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2025-11-13 · Disposition to issuer · Disposed 33,390 · Balance 0 F1: This option was cancelled pursuant to that certain Purchase Agreement, dated August 3, 2025, by and between the Issuer and XOMA Royalty Corporation (as amended, the "Purchase Agreement") in exchange for cash and contingent value rights ("CVRs") (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to (i) the excess of $1.04 over the per share exercise price of such option multiplied by the total number of shares underlying such in option and (ii) one CVR per share underlying such in-the-money option.

Filing footnotes · ownership attribution and instrument terms

F1: This option was cancelled pursuant to that certain Purchase Agreement, dated August 3, 2025, by and between the Issuer and XOMA Royalty Corporation (as amended, the "Purchase Agreement") in exchange for cash and contingent value rights ("CVRs") (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to (i) the excess of $1.04 over the per share exercise price of such option multiplied by the total number of shares underlying such in option and (ii) one CVR per share underlying such in-the-money option.

Sucampo Pharmaceuticals, Inc.

Report date February 13, 2018 · Filed February 13, 2018

Section 16 reporting ended · disclosed 2018-02-13. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common Stock, Class ASEC Table I · non-derivative	Direct	Reported balance After 2018-02-13 transaction · row 1 1 source row Row 1 · 2018-02-13 · Disposition to issuer · Disposed 44,856 · Balance 0 F1: This common stock was purchased for $18.00 per share share in cash, subject to any required withholding of taxes and without interest, upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to that certain Agreement and Plan of Merger by and among Mallinckrodt plc, Sun Acquisition Co. and Sucampo Pharmaceuticals, Inc. dated December 23, 2017 (the "Merger Agreement").
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.33 · Expires 2024-10-27	Direct	Reported balance After 2018-02-13 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2018-02-13 · Disposition to issuer · Disposed 250,000 · Balance 0 F2: This option was cancelled and converted into the right to receive in cash the amount per share by which $18.00 exceeds the exercise price of the option, subject to any applicable tax witholdings (such amount, the "Option Spread"), upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to the Merger Agreement. The Option Spread for the unvested portion of the option, if any, will be paid in accordance with the schedule described in the Merger Agreement.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.82 · Expires 2025-03-04	Direct	Reported balance After 2018-02-13 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2018-02-13 · Disposition to issuer · Disposed 38,500 · Balance 0 F2: This option was cancelled and converted into the right to receive in cash the amount per share by which $18.00 exceeds the exercise price of the option, subject to any applicable tax witholdings (such amount, the "Option Spread"), upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to the Merger Agreement. The Option Spread for the unvested portion of the option, if any, will be paid in accordance with the schedule described in the Merger Agreement.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.80 · Expires 2026-03-02	Direct	Reported balance After 2018-02-13 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2018-02-13 · Disposition to issuer · Disposed 87,203 · Balance 0 F2: This option was cancelled and converted into the right to receive in cash the amount per share by which $18.00 exceeds the exercise price of the option, subject to any applicable tax witholdings (such amount, the "Option Spread"), upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to the Merger Agreement. The Option Spread for the unvested portion of the option, if any, will be paid in accordance with the schedule described in the Merger Agreement.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.85 · Expires 2027-03-02	Direct	Reported balance After 2018-02-13 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2018-02-13 · Disposition to issuer · Disposed 133,000 · Balance 0 F2: This option was cancelled and converted into the right to receive in cash the amount per share by which $18.00 exceeds the exercise price of the option, subject to any applicable tax witholdings (such amount, the "Option Spread"), upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to the Merger Agreement. The Option Spread for the unvested portion of the option, if any, will be paid in accordance with the schedule described in the Merger Agreement.

Filing footnotes · ownership attribution and instrument terms

F1: This common stock was purchased for $18.00 per share share in cash, subject to any required withholding of taxes and without interest, upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to that certain Agreement and Plan of Merger by and among Mallinckrodt plc, Sun Acquisition Co. and Sucampo Pharmaceuticals, Inc. dated December 23, 2017 (the "Merger Agreement").

F2: This option was cancelled and converted into the right to receive in cash the amount per share by which $18.00 exceeds the exercise price of the option, subject to any applicable tax witholdings (such amount, the "Option Spread"), upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to the Merger Agreement. The Option Spread for the unvested portion of the option, if any, will be paid in accordance with the schedule described in the Merger Agreement.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
January 02, 2026 Filed Jan 6, 2026 16:00 UTC	Cue Biopharma, Inc. CUE · Entity 6301	GrantStock Option (right to buy) · Derivative	24,400	$0.00 Strike: $0.34	$0.00	Disclosure SEC source: 0001193125-26-004359 · ownership.xml · derivative · entry 1 Kiener Peter A · CIK 0001328146 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,400 Underlying: Common Stock · 24,400 shares Expires 2036-01-01 F1 · shares: Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy. F2 · derivative.exercise_date: This stock option becomes fully exercisable on the first anniversary of the grant date. Read SEC document
November 13, 2025 Filed Nov 17, 2025 16:30 UTC	LAVA Therapeutics NV LVTX · Entity 73047	Disposition to issuerShare Options (Right to Buy) · Derivative	33,390	$0.00 Strike: $0.93	$0.00	Disclosure SEC source: 0001328146-25-000004 · form4-11172025_041111.xml · derivative · entry 1 Kiener Peter A · CIK 0001328146 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 33,390 shares Expires 2035-02-12 F1 · derivative.exercise_date: This option was cancelled pursuant to that certain Purchase Agreement, dated August 3, 2025, by and between the Issuer and XOMA Royalty Corporation (as amended, the "Purchase Agreement") in exchange for cash and contingent value rights ("CVRs") (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to (i) the excess of $1.04 over the per share exercise price of such option multiplied by the total number of shares underlying such in option and (ii) one CVR per share underlying such in-the-money option. Read SEC document
February 13, 2025 Filed Feb 18, 2025 20:15 UTC	LAVA Therapeutics NV LVTX · Entity 73047	GrantCommon Shares (Right to Buy) · Derivative	33,390	$0.00 Strike: $0.93	$0.00	Disclosure SEC source: 0001415889-25-004529 · form4-02182025_080214.xml · derivative · entry 1 Kiener Peter A · CIK 0001328146 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,390 Underlying: Common Shares · 33,390 shares Expires 2035-02-12 F1 · derivative.exercise_date: 100% of the shares underlying the option will vest on February 13, 2026, provided the Reporting Person remains in a service relationship with the Issuer or a subsidiary of the Issuer on such vesting date. Read SEC document
January 02, 2025 Filed Jan 3, 2025 16:00 UTC	Cue Biopharma, Inc. CUE · Entity 6301	GrantStock Option (right to buy) · Derivative	24,400	$0.00 Strike: $1.09	$0.00	Disclosure SEC source: 0000950170-25-001105 · ownership.xml · derivative · entry 1 Kiener Peter A · CIK 0001328146 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,400 Underlying: Common Stock · 24,400 shares Expires 2035-01-01 F1 · shares: Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy. F2 · derivative.exercise_date: This option was granted on January 2, 2025. The option is scheduled to vest as to 50% of the underlying shares on the six-month anniversary of the grant date and as to the remaining 50% on the first anniversary of the grant date. Read SEC document
January 02, 2024 Filed Jan 4, 2024 16:02 UTC	Cue Biopharma, Inc. CUE · Entity 6301	GrantStock Option (right to buy) · Derivative	24,400	$0.00 Strike: $2.78	$0.00	Disclosure SEC source: 0000950170-24-001830 · ownership.xml · derivative · entry 1 Kiener Peter A · CIK 0001328146 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,400 Underlying: Common Stock · 24,400 shares Expires 2034-01-01 F1 · shares: Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy. F2 · derivative.exercise_date: This option was granted on January 2, 2024. The shares underlying the option are scheduled to vest in full on the anniversary date of the grant date. Read SEC document
June 21, 2023 Filed Jun 23, 2023 16:46 UTC	PALVELLA THERAPEUTICS, INC. PIRS · Entity 4452	GrantStock Option (right to buy) · Derivative	40,000	$0.00 Strike: $0.26	$0.00	Disclosure SEC source: 0001437749-23-018282 · rdgdoc.xml · derivative · entry 1 Kiener Peter A · CIK 0001328146 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2033-06-21 F1 · derivative.exercise_date: The stock option will vest as to 100% of the underlying shares on the date of the Company's 2024 annual stockholders meeting, subject to the Reporting Person's continued service as a director through the vesting date. Read SEC document
March 23, 2023 Filed Mar 27, 2023 16:05 UTC	Cue Biopharma, Inc. CUE · Entity 6301	Exercise / conversionStock Option (right to buy) · Derivative	9,682	$0.00 Strike: $2.86	$0.00	Disclosure SEC source: 0001209191-23-021201 · doc4.xml · derivative · entry 3 Kiener Peter A · CIK 0001328146 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,062 Underlying: Common Stock · 9,682 shares Expires 2023-03-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This Stock Option became exercisable in five equal annual installments beginning March 23, 2017 and is fully vested. This stock option expired on March 23, 2023. Read SEC document
March 23, 2023 Filed Mar 27, 2023 16:05 UTC	Cue Biopharma, Inc. CUE · Entity 6301	SaleCommon Stock	9,325	$3.28	$30,586.00	Disclosure SEC source: 0001209191-23-021201 · doc4.xml · nonDerivative · entry 2 Kiener Peter A · CIK 0001328146 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 357 F1 · kind: Sale to cover exercise price of cashless exercise of stock option. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.20 to $3.31, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document
March 23, 2023 Filed Mar 27, 2023 16:05 UTC	Cue Biopharma, Inc. CUE · Entity 6301	Exercise / conversionCommon Stock	9,682	$2.86	$27,690.52	Disclosure SEC source: 0001209191-23-021201 · doc4.xml · nonDerivative · entry 1 Kiener Peter A · CIK 0001328146 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,682 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 03, 2023 Filed Jan 5, 2023 16:10 UTC	Cue Biopharma, Inc. CUE · Entity 6301	GrantStock Option (right to buy) · Derivative	10,000	$0.00 Strike: $2.66	$0.00	Disclosure SEC source: 0001209191-23-001789 · doc4.xml · derivative · entry 1 Kiener Peter A · CIK 0001328146 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2033-01-02 F1 · shares: Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy. F2 · derivative.exercise_date: This option was granted on January 3, 2023. The shares underlying the option are scheduled to vest in full on the anniversary date of the grant date. Read SEC document
June 22, 2022 Filed Jun 24, 2022 19:03 UTC	PALVELLA THERAPEUTICS, INC. PIRS · Entity 4452	GrantStock Option (right to buy) · Derivative	40,000	$0.00 Strike: $1.82	$0.00	Disclosure SEC source: 0001583648-22-000051 · wf-form4_165611178802913.xml · derivative · entry 1 Kiener Peter A · CIK 0001328146 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2032-06-22 F1 · derivative.exercise_date: The stock option will vest as to 100% of the underlying shares on the date of the Company's 2023 annual stockholders meeting, subject to the Reporting Person's continued service as a director through the vesting date. Read SEC document
January 03, 2022 Filed Jan 5, 2022 20:27 UTC	Cue Biopharma, Inc. CUE · Entity 6301	GrantStock Option (right to buy) · Derivative	10,000	$0.00 Strike: $12.28	$0.00	Disclosure SEC source: 0000899243-22-001052 · doc4.xml · derivative · entry 1 Kiener Peter A · CIK 0001328146 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2032-01-02 F1 · shares: Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy. F2 · derivative.exercise_date: This option was granted on January 3, 2022. The shares underlying the option are scheduled to vest in full on the anniversary of the grant date. Read SEC document
November 16, 2021 Filed Nov 17, 2021 17:00 UTC	Cue Biopharma, Inc. CUE · Entity 6301	Exercise / conversionStock Option (right to buy) · Derivative	1,361	$0.00 Strike: $2.86	$0.00	Disclosure SEC source: 0000899243-21-045070 · doc4.xml · derivative · entry 6 Kiener Peter A · CIK 0001328146 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,744 Underlying: Common Stock · 1,361 shares Expires 2023-03-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 18, 2020. F4 · derivative.exercise_date: The option vests in five equal annual installments beginning March 23, 2017. Read SEC document
November 16, 2021 Filed Nov 17, 2021 17:00 UTC	Cue Biopharma, Inc. CUE · Entity 6301	SaleCommon Stock	1,361	$18.02	$24,525.22	Disclosure SEC source: 0000899243-21-045070 · doc4.xml · nonDerivative · entry 4 Kiener Peter A · CIK 0001328146 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 18, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.86 to $18.31, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (3) to this Form 4. Read SEC document
November 16, 2021 Filed Nov 17, 2021 17:00 UTC	Cue Biopharma, Inc. CUE · Entity 6301	Exercise / conversionCommon Stock	1,361	$2.86	$3,892.46	Disclosure SEC source: 0000899243-21-045070 · doc4.xml · nonDerivative · entry 3 Kiener Peter A · CIK 0001328146 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,361 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 18, 2020. Read SEC document
November 15, 2021 Filed Nov 17, 2021 17:00 UTC	Cue Biopharma, Inc. CUE · Entity 6301	Exercise / conversionStock Option (right to buy) · Derivative	18,815	$0.00 Strike: $2.86	$0.00	Disclosure SEC source: 0000899243-21-045070 · doc4.xml · derivative · entry 5 Kiener Peter A · CIK 0001328146 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,105 Underlying: Common Stock · 18,815 shares Expires 2023-03-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 18, 2020. F4 · derivative.exercise_date: The option vests in five equal annual installments beginning March 23, 2017. Read SEC document
November 15, 2021 Filed Nov 17, 2021 17:00 UTC	Cue Biopharma, Inc. CUE · Entity 6301	SaleCommon Stock	18,815	$17.92	$337,164.80	Disclosure SEC source: 0000899243-21-045070 · doc4.xml · nonDerivative · entry 2 Kiener Peter A · CIK 0001328146 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 18, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.86 to $18.20, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document
November 15, 2021 Filed Nov 17, 2021 17:00 UTC	Cue Biopharma, Inc. CUE · Entity 6301	Exercise / conversionCommon Stock	18,815	$2.86	$53,810.90	Disclosure SEC source: 0000899243-21-045070 · doc4.xml · nonDerivative · entry 1 Kiener Peter A · CIK 0001328146 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,815 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 18, 2020. Read SEC document
June 25, 2021 Filed Jun 29, 2021 17:26 UTC	PALVELLA THERAPEUTICS, INC. PIRS · Entity 4452	GrantStock Option (right to buy) · Derivative	40,000	$0.00 Strike: $4.00	$0.00	Disclosure SEC source: 0001562180-21-004560 · primarydocument.xml · derivative · entry 1 Kiener Peter A · CIK 0001328146 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2031-06-25 F1 · derivative.exercise_date: The stock option will vest as to 100% of the underlying shares on the date of the Company's 2022 annual stockholders meeting, subject to the Reporting Person's continued service as a director through the vesting date. Read SEC document
January 04, 2021 Filed Jan 6, 2021 16:44 UTC	Cue Biopharma, Inc. CUE · Entity 6301	GrantStock Option (right to buy) · Derivative	10,000	$0.00 Strike: $12.36	$0.00	Disclosure SEC source: 0000899243-21-000711 · doc4.xml · derivative · entry 1 Kiener Peter A · CIK 0001328146 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-01-03 F1 · shares: Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy. F2 · derivative.exercise_date: This option was granted on January 4, 2021. The shares underlying the option are scheduled to vest in full on the anniversary of the grant date. Read SEC document
June 23, 2020 Filed Jun 25, 2020 16:45 UTC	PALVELLA THERAPEUTICS, INC. PIRS · Entity 4452	GrantStock Options (Right to buy) · Derivative	40,000	$0.00 Strike: $3.27	$0.00	Disclosure SEC source: 0001562180-20-004688 · primarydocument.xml · derivative · entry 1 Kiener Peter A · CIK 0001328146 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2030-06-23 F1 · derivative.exercise_date: The stock option will vest as to 100% of the underlying shares on June 23, 2021, subject to the Reporting Person's continued service as a director through the vesting date. Read SEC document
January 25, 2020 Filed Jan 28, 2020 16:22 UTC	PALVELLA THERAPEUTICS, INC. PIRS · Entity 4452	GrantStock Option (right to buy) · Derivative	20,000	$0.00 Strike: $3.23	$0.00	Disclosure SEC source: 0001562180-20-000623 · primarydocument.xml · derivative · entry 1 Kiener Peter A · CIK 0001328146 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-01-25 F1 · derivative.exercise_date: The stock option will vest as to 100% of the underlying shares on January 25, 2021, subject to the Reporting Person's continued service as a director through the vesting date. Read SEC document
January 02, 2020 Filed Jan 6, 2020 17:55 UTC	Cue Biopharma, Inc. CUE · Entity 6301	GrantStock Option (right to buy) · Derivative	8,000	$0.00 Strike: $16.31	$0.00	Disclosure SEC source: 0001209191-20-002060 · doc4.xml · derivative · entry 1 Kiener Peter A · CIK 0001328146 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2030-01-02 F1 · shares: Represents a stock option award granted on January 2, 2020 pursuant to the Issuer's Director Compensation Policy. Read SEC document
January 25, 2019 Filed Jan 29, 2019 17:37 UTC	PALVELLA THERAPEUTICS, INC. PIRS · Entity 4452	GrantStock Option (right to buy) · Derivative	20,000	$0.00 Strike: $2.74	$0.00	Disclosure SEC source: 0001562180-19-000572 · primarydocument.xml · derivative · entry 1 Kiener Peter A · CIK 0001328146 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2029-01-25 F1 · derivative.exercise_date: The stock option will vest as to 100% of the underlying shares on January 25, 2020, subject to the Reporting Person's continued service as a director through the vesting date. Read SEC document
January 02, 2019 Filed Jan 3, 2019 18:38 UTC	Cue Biopharma, Inc. CUE · Entity 6301	GrantStock Option (right to buy) · Derivative	8,000	$0.00 Strike: $5.16	$0.00	Disclosure SEC source: 0001209191-19-001328 · doc4.xml · derivative · entry 1 Kiener Peter A · CIK 0001328146 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2026-01-02 Read SEC document
October 24, 2018 Filed Oct 25, 2018 17:19 UTC	PALVELLA THERAPEUTICS, INC. PIRS · Entity 4452	GrantStock Option (right to buy) · Derivative	30,000	$0.00 Strike: $4.46	$0.00	Disclosure SEC source: 0001562180-18-004280 · primarydocument.xml · derivative · entry 1 Kiener Peter A · CIK 0001328146 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2028-10-24 F1 · derivative.exercise_date: The stock option will vest as to 100% of the underlying shares on October 24, 2019, subject to the Reporting Person's continued service as a director through the vesting date. Read SEC document
June 12, 2018 Filed Jun 14, 2018 17:30 UTC	Cue Biopharma, Inc. CUE · Entity 6301	Exercise / conversionStock Option (right to buy) · Derivative	9,600	$0.00 Strike: $14.24	$0.00	Disclosure SEC source: 0001209191-18-037808 · doc4.xml · derivative · entry 1 Kiener Peter A · CIK 0001328146 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,600 Underlying: Common Stock · 9,600 shares Expires 2025-06-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 13, 2018 Filed Feb 13, 2018 16:51 UTC	Sucampo Pharmaceuticals, Inc. SCMP · Entity 169352	Disposition to issuerStock Option (right to buy) · Derivative	133,000	$6.15 Strike: $11.85	$817,950.00	Disclosure SEC source: 0001171843-18-001104 · formfour.xml · derivative · entry 5 Kiener Peter A · CIK 0001328146 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 133,000 shares Expires 2027-03-02 F2 · derivative.exercise_date: This option was cancelled and converted into the right to receive in cash the amount per share by which $18.00 exceeds the exercise price of the option, subject to any applicable tax witholdings (such amount, the "Option Spread"), upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to the Merger Agreement. The Option Spread for the unvested portion of the option, if any, will be paid in accordance with the schedule described in the Merger Agreement. Read SEC document
February 13, 2018 Filed Feb 13, 2018 16:51 UTC	Sucampo Pharmaceuticals, Inc. SCMP · Entity 169352	Disposition to issuerStock Option (right to buy) · Derivative	87,203	$4.20 Strike: $13.80	$366,252.60	Disclosure SEC source: 0001171843-18-001104 · formfour.xml · derivative · entry 4 Kiener Peter A · CIK 0001328146 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 87,203 shares Expires 2026-03-02 F2 · derivative.exercise_date: This option was cancelled and converted into the right to receive in cash the amount per share by which $18.00 exceeds the exercise price of the option, subject to any applicable tax witholdings (such amount, the "Option Spread"), upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to the Merger Agreement. The Option Spread for the unvested portion of the option, if any, will be paid in accordance with the schedule described in the Merger Agreement. Read SEC document
February 13, 2018 Filed Feb 13, 2018 16:51 UTC	Sucampo Pharmaceuticals, Inc. SCMP · Entity 169352	Disposition to issuerStock Option (right to buy) · Derivative	38,500	$3.18 Strike: $14.82	$122,430.00	Disclosure SEC source: 0001171843-18-001104 · formfour.xml · derivative · entry 3 Kiener Peter A · CIK 0001328146 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 38,500 shares Expires 2025-03-04 F2 · derivative.exercise_date: This option was cancelled and converted into the right to receive in cash the amount per share by which $18.00 exceeds the exercise price of the option, subject to any applicable tax witholdings (such amount, the "Option Spread"), upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to the Merger Agreement. The Option Spread for the unvested portion of the option, if any, will be paid in accordance with the schedule described in the Merger Agreement. Read SEC document
February 13, 2018 Filed Feb 13, 2018 16:51 UTC	Sucampo Pharmaceuticals, Inc. SCMP · Entity 169352	Disposition to issuerStock Option (right to buy) · Derivative	250,000	$9.67 Strike: $8.33	$2,417,500.00	Disclosure SEC source: 0001171843-18-001104 · formfour.xml · derivative · entry 2 Kiener Peter A · CIK 0001328146 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 250,000 shares Expires 2024-10-27 F2 · derivative.exercise_date: This option was cancelled and converted into the right to receive in cash the amount per share by which $18.00 exceeds the exercise price of the option, subject to any applicable tax witholdings (such amount, the "Option Spread"), upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to the Merger Agreement. The Option Spread for the unvested portion of the option, if any, will be paid in accordance with the schedule described in the Merger Agreement. Read SEC document
February 13, 2018 Filed Feb 13, 2018 16:51 UTC	Sucampo Pharmaceuticals, Inc. SCMP · Entity 169352	Disposition to issuerCommon Stock, Class A	44,856	$18.00	$807,408.00	Disclosure SEC source: 0001171843-18-001104 · formfour.xml · nonDerivative · entry 1 Kiener Peter A · CIK 0001328146 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: This common stock was purchased for $18.00 per share share in cash, subject to any required withholding of taxes and without interest, upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to that certain Agreement and Plan of Merger by and among Mallinckrodt plc, Sun Acquisition Co. and Sucampo Pharmaceuticals, Inc. dated December 23, 2017 (the "Merger Agreement"). Read SEC document
December 31, 2017 Filed Jan 4, 2018 17:16 UTC	Sucampo Pharmaceuticals, Inc. SCMP · Entity 169352	GrantCommon Stock, Class A (ESPP)	329	$9.10	$2,993.90	Disclosure SEC source: 0001171843-18-000178 · formfour.xml · nonDerivative · entry 1 Kiener Peter A · CIK 0001328146 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,856 F1 · security: The reporting person is voluntarily reporting the acquisition of common stock pursuant to the issuer's Employee Stock Purchase Plan (ESPP) for the period October 1, 2017 through December 31, 2017. This transaction is exempt under Rule 16(b)-3(c). F2 · price: In accordance with the ESPP, these shares were purchased at 85% of the July 3, 2017 closing price of the issuer's common stock. Read SEC document
December 28, 2017 Filed Jan 2, 2018 17:00 UTC	Sucampo Pharmaceuticals, Inc. SCMP · Entity 169352	Tax withholdingCommon Stock, Class A	27,496	$17.98	$494,378.08	Disclosure SEC source: 0001171843-18-000049 · formfour.xml · nonDerivative · entry 1 Kiener Peter A · CIK 0001328146 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,527 F1 · shares: The transaction reported represents the non-discretionary withholding of shares to satisfy the reporting person's tax withholding obligations in connection with the non-reportable vesting and settlement of restricted stock units. F2 · shares: Common stock originally granted consists of restricted stocked units; this award was originally scheduled to vest on March 2, 2020, but was accelerated to vest on December 28, 2017. Read SEC document
December 07, 2017 Filed Dec 11, 2017 17:30 UTC	Sucampo Pharmaceuticals, Inc. SCMP · Entity 169352	Exercise / conversionEmployee Stock Option (right to buy) · Derivative	50,000	$0.00 Strike: $8.33	$0.00	Disclosure SEC source: 0001171843-17-007595 · formfour.xml · derivative · entry 3 Kiener Peter A · CIK 0001328146 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,567 Underlying: Class A Common Stock · 50,000 shares Expires 2024-10-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Grant has a graded vesting schedule. Date Exercisable will vary for each vesting tranche. Read SEC document
December 07, 2017 Filed Dec 11, 2017 17:30 UTC	Sucampo Pharmaceuticals, Inc. SCMP · Entity 169352	SaleCommon Stock, Class A	50,000	$16.50	$825,000.00	Disclosure SEC source: 0001171843-17-007595 · formfour.xml · nonDerivative · entry 2 Kiener Peter A · CIK 0001328146 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,023 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5 1 trading plan adopted by the Reporting Person. F2 · price: Multiple lots for the same price for this order have been combined. Read SEC document
December 07, 2017 Filed Dec 11, 2017 17:30 UTC	Sucampo Pharmaceuticals, Inc. SCMP · Entity 169352	Exercise / conversionCommon Stock, Class A	50,000	$8.33	$416,500.00	Disclosure SEC source: 0001171843-17-007595 · formfour.xml · nonDerivative · entry 1 Kiener Peter A · CIK 0001328146 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,023 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
September 30, 2017 Filed Oct 5, 2017 16:40 UTC	Sucampo Pharmaceuticals, Inc. SCMP · Entity 169352	GrantCommon Stock, Class A (ESPP)	330	$9.10	$3,003.00	Disclosure SEC source: 0001171843-17-005959 · formfour.xml · nonDerivative · entry 1 Kiener Peter A · CIK 0001328146 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,023 F1 · security: The reporting person is voluntarily reporting the acquisition of common stock pursuant to the issuer's Employee Stock Purchase Plan (ESPP) for the period July 1, 2017 through September 30, 2017. This transaction is exempt under Rule 16(b)-3(c). F2 · price: In accordance with the ESPP, these shares were purchased at 85% of the July 3, 2017 closing price of the issuer's common stock. Read SEC document
June 30, 2017 Filed Jul 7, 2017 16:46 UTC	Sucampo Pharmaceuticals, Inc. SCMP · Entity 169352	GrantCommon Stock, Class A (ESPP)	336	$8.93	$3,000.48	Disclosure SEC source: 0001171843-17-004004 · formfour.xml · nonDerivative · entry 1 Kiener Peter A · CIK 0001328146 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,693 F1 · security: The reporting person is voluntarily reporting the acquisition of common stock pursuant to the issuer's Employee Stock Purchase Plan (ESPP) for the period April 1, 2017 through June 30, 2017. This transaction is exempt under Rule 16(b)-3(c). F2 · price: In accordance with the ESPP, these shares were purchased at 85% of the June 30, 2017 closing price of the issuer's common stock. Read SEC document
March 31, 2017 Filed May 10, 2017 16:03 UTC	Sucampo Pharmaceuticals, Inc. SCMP · Entity 169352	GrantCommon Stock, Class A (ESPP)	321	$9.35	$3,001.35	Disclosure SEC source: 0001171843-17-002920 · formfour.xml · nonDerivative · entry 1 Kiener Peter A · CIK 0001328146 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,357 F1 · security: The reporting person is voluntarily reporting the acquisition of common stock pursuant to the issuer's Employee Stock Purchase Plan (ESPP) for the period January 1, 2017 through March 31, 2017. This transaction is exempt under Rule 16(b)-3(c). F2 · price: In accordance with the ESPP, these shares were purchased at 85% of the March 31, 2017 closing price of the issuer's common stock. Read SEC document
March 06, 2017 Filed Mar 8, 2017 17:02 UTC	Sucampo Pharmaceuticals, Inc. SCMP · Entity 169352	GrantEmployee Stock Option (right to buy) · Derivative	133,000	$0.00 Strike: $11.85	$0.00	Disclosure SEC source: 0001171843-17-001363 · f4_kiener030817.xml · derivative · entry 2 Kiener Peter A · CIK 0001328146 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 626,270 Underlying: Class A Common Stock · 133,000 shares Expires 2027-03-02 F2 · derivative.exercise_date: The option will vest over a four-year period, with 25% vesting on March 2, 2018, and the remaining 75% vesting in equal monthly increments over the three-year period thereafter. Read SEC document
March 06, 2017 Filed Mar 8, 2017 17:02 UTC	Sucampo Pharmaceuticals, Inc. SCMP · Entity 169352	GrantCommon stock	70,000	$0.00	$0.00	Disclosure SEC source: 0001171843-17-001363 · f4_kiener030817.xml · nonDerivative · entry 1 Kiener Peter A · CIK 0001328146 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 F1 · security: Common stock granted consists of restricted stock units that vest on March 2, 2020. Read SEC document
December 31, 2016 Filed Jan 6, 2017 16:03 UTC	Sucampo Pharmaceuticals, Inc. SCMP · Entity 169352	GrantCommon Stock, Class A (ESPP)	287	$10.46	$3,002.02	Disclosure SEC source: 0001171843-17-000125 · formfour.xml · nonDerivative · entry 1 Kiener Peter A · CIK 0001328146 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,036 F1 · security: The reporting person is voluntarily reporting the acquisition of common stock pursuant to the issuer's Employee Stock Purchase Plan (ESPP) for the period October 1, 2016 through December 31, 2016. This transaction is exempt under Rule 16(b)-3(c). F2 · price: In accordance with the ESPP, these shares were purchased at 85% of the September 30, 2016 closing price of the issuer's common stock. Read SEC document
September 30, 2016 Filed Oct 21, 2016 16:06 UTC	Sucampo Pharmaceuticals, Inc. SCMP · Entity 169352	GrantCommon Stock, Class A (ESPP)	320	$9.38	$3,001.60	Disclosure SEC source: 0001171843-16-012576 · f4_kiener102116.xml · nonDerivative · entry 1 Kiener Peter A · CIK 0001328146 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 749 F1 · security: The reporting person is voluntarily reporting the acquisition of common stock pursuant to the issuer's Employee Stock Purchase Plan (ESPP) for the period July 1, 2016 through September 30, 2016. This transaction is exempt under Rule 16(b)-3(c). F2 · price: In accordance with the ESPP, these shares were purchased at 85% of the July 1, 2016 closing price of the issuer's common stock. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.